Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 30;107(9):2037–2050. doi: 10.3324/haematol.2022.280953

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright© 2022 Ferrata Storti Foundation

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

PMC Copyright notice

Figure 3. — Management of IgM-associated amyloidosis. *Histological assessment includes targeting affecting organ, consider abdominal fat biopsy. Exclude other acquired and hereditary amyloidoses. **Organ assessment includes comprehensive evaluation of organs including cardiac, renal, neurological, gastrointestinal and soft tissue involvement. M-protein: monoclonal protein; SPEP: serum protein electrophoresis; SFLC: serum free light chains; LPL: lymphoplasmacytic lymphoma; CT: computed tomography; PET: positron emission tomography; MRI: magnetic resonance imaging; PPCN: pure plasma cell neoplasm; R-Bendamustine: rituximab plus bendamustine; BEAM: carmustine, etoposide, cytarabine, melphalan; Mel, melphalan; ASCT: autologous stem cell transplantation; AL: AL amyloidosis.